Patents by Inventor Tze Mun Loo

Tze Mun Loo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
    Patent number: 10583129
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 10, 2020
    Assignee: AskAt Inc.
    Inventors: Naoko Ohtani, Fumitaka Kamachi, Tze Mun Loo, Shinichi Koizumi, Takako Okumura
  • USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER
    Publication number: 20190365680
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist(s), and may include one or more other active agents and/or therapies.
    Type: Application
    Filed: November 2, 2017
    Publication date: December 5, 2019
    Inventors: Naoko OHTANI, Fumitaka KAMACHI, Tze Mun LOO, Shinichi KOIZUMI, Takako OKUMURA
  • USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER
    Publication number: 20190269663
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Application
    Filed: May 21, 2019
    Publication date: September 5, 2019
    Inventors: Naoko OHTANI, Fumitaka KAMACHI, Tze Mun LOO, Shinichi KOIZUMI, Takako OKUMURA
  • Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
    Patent number: 10342785
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 9, 2019
    Assignee: AskAt Inc.
    Inventors: Naoko Ohtani, Fumitaka Kamachi, Tze Mun Loo, Shinichi Koizumi, Takako Okumura
  • USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NASH-ASSOCIATED LIVER CANCER
    Publication number: 20180125832
    Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 10, 2018
    Inventors: Naoko OHTANI, Fumitaka KAMACHI, Tze Mun LOO, Shinichi KOIZUMI, Takako OKUMURA
  • Method for screening food ingredients and food compositions
    Patent number: 9856507
    Abstract: The present invention provides a method for screening for a food ingredient or a food composition that reduces a cancer risk and inhibits cancer development. A substance that reduces a cancer risk is screened by administering a candidate substance and analyzing alteration in gut microbiota or a metabolite produced by an intestinal bacterium. Also, candidate substances are screened by adding each candidate substance to a bacterial culture system and analyzing its effect on a bacterium involved in cancer development.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: January 2, 2018
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Eiji Hara, Naoko Ohtani, Shin Yoshimoto, Tze Mun Loo
  • Method for examination of carcinogenic risk
    Patent number: 9670550
    Abstract: The present invention provides a method capable of detecting a cancer and/or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and/or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: June 6, 2017
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Eiji Hara, Naoko Ohtani, Shin Yoshimoto, Tze Mun Loo
  • METHOD FOR SCREENING FOOD INGREDIENTS AND FOOD COMPOSITIONS
    Publication number: 20160002699
    Abstract: The present invention provides a method for screening for a food ingredient or a food composition that reduces a cancer risk and inhibits cancer development. A substance that reduces a cancer risk is screened by administering a candidate substance and analyzing alteration in gut microbiota or a metabolite produced by an intestinal bacterium. Also, candidate substances are screened by adding each candidate substance to a bacterial culture system and analyzing its effect on a bacterium involved in cancer development.
    Type: Application
    Filed: February 10, 2014
    Publication date: January 7, 2016
    Inventors: Eiji Hara, Naoko Ohtani, Shin Yoshimoto, Tze Mun Loo
  • METHOD FOR EXAMINATION OF CARCINOGENIC RISK
    Publication number: 20150376716
    Abstract: The present invention provides a method capable of detecting a cancer and/or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and/or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.
    Type: Application
    Filed: February 10, 2014
    Publication date: December 31, 2015
    Inventors: Eiji Hara, Naoko Ohtani, Shin Yoshimoto, Tze Mun Loo